Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.7.0.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2017
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following tables summarize, for the periods indicated, operating results by reportable segment:
 
Cost of goods sold is directly related to product sales only. Revenues derived from co-promote revenue had no cost of goods sold
 
 
 
 
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
and
 
 
 
 
 
 
 
Dermatology
 
Biotechnology
 
 
 
 
 
($ in thousands)
 
Products
 
Product
 
 
 
 
 
Three Months Ended March 31, 2017
 
Sales
 
Development
 
National
 
Consolidated
 
Net Revenue
 
$
2,085
 
$
693
 
$
41,904
 
$
44,682
 
Direct cost of goods
 
 
(469)
 
 
-
 
 
-
 
 
(469)
 
Sales and marketing costs
 
 
(2,267)
 
 
-
 
 
-
 
 
(2,267)
 
Research and development
 
 
-
 
 
(8,404)
 
 
-
 
 
(8,404)
 
General and administrative
 
 
(319)
 
 
(7,666)
 
 
-
 
 
(7,985)
 
National Expenses
 
 
-
 
 
-
 
 
(43,134)
 
 
(43,134)
 
Segment loss from operations
 
$
(970)
 
$
(15,377)
 
$
(1,230)
 
$
(17,577)
 
Segment assets
 
$
4,039
 
$
159,175
 
$
48,697
 
$
211,911